ArticleEuropean journal of breast health2025
Predictive Value of Dimensional and Functional MRI Parameters on Mid-Treatment MRI for Pathologic Complete Response in Breast Cancer.
Article in European journal of breast health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the predictive performance of dimensional and functional magnetic resonance imaging (MRI) parameters obtained from mid-treatment breast MRI for forecasting pathologic complete response (pCR) in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy (NAC). Materials and Methods: Sixty-five women with LABC who underwent NAC followed by surgery were retrospectively included. Quantitative MRI parameters-including % change (Δ%) in longest diameter, bidimensional size, tumor volume, apparent diffusion coefficient (ADC), and enhancement percentage (Epeak) -were calculated between pre- and mid-NAC MRI. Receiver operating characteristic (ROC) analysis and logistic regression were used to identify predictors of pCR. Logistic regression and ROC analysis (with DeLong's test) were used to assess associations with pCR and compare area under the curves (AUCs). Results: pCR was achieved in 19 of 65 patients (29%). Compared to non-pCR cases, patients with pCR showed significantly greater reductions in tumor size and Epeak, and larger increases in ADC value (all Conclusion: Mid-treatment MRI biomarkers, particularly Δ% longest diameter and Δ% ADC value, are effective early predictors of pCR and may support individualized treatment strategies during NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.